| Stage | SURG | % of rev | VZ | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $21M | 100.00% | $34.3B | 100.00% | VZ ×1648.95 |
| Gross profit | $11M | 54.10% | $21.2B | 61.86% | VZ +7.8pp |
| Operating income | $2M | 9.45% | $8.7B | 25.21% | VZ +15.8pp |
| Pre-tax income | $2M | 9.35% | $6.8B | 19.87% | VZ +10.5pp |
| Net income | $2M | 7.35% | $5.3B | 15.50% | VZ +8.2pp |
| Stage | SURG | VZ | Gap · A − B |
|---|---|---|---|
| Revenue | $21M100.00% | $34.3B100.00% | VZ ×1648.95 |
| Gross profit | 54.10%$11M | 61.86%$21.2B | VZ +7.8pp |
| Operating income | 9.45%$2M | 25.21%$8.7B | VZ +15.8pp |
| Pre-tax income | 9.35%$2M | 19.87%$6.8B | VZ +10.5pp |
| Net income |
| 7.35%$2M |
| 15.50%$5.3B |
| VZ +8.2pp |
None
No disclosed counterparties: SURG.